Poor glycaemic control is directly related to loss of MM, strength, and decreased general physical performance
Conclusion The SELECT study strengthens the view of GLP-1 medications as more than weight-loss aids
By binding to and activating the GLP-1 receptor, it mimics the natural incretin hormone GLP-1 to promote appetite suppression, delay gastric emptying, and increase insulin secretion while stabilizing glucose levels #Dapagliflozin (#Farxiga (US), #Forxiga (EU) by AstraZeneca) is an oral, once-daily SGLT2 inhibitor
Users have shared reports of: Less joint stiffness during movement More comfort following workouts Decreased post-meal bloating Enhanced sense of physical "balance" or reduced localized tension Again, these outcomes are based on anecdotal accounts and are not guaranteed
If a batch does not meet this standard, it is rejected and never shipped to customers
(2017) published in Diabetes, Obesity and Metabolism demonstrated that semaglutide specifically reduces appetite, food cravings, and the desire to eat energy-dense foods through central nervous system mechanisms